Ascendis Pharma announced on Monday that the US Food & Drug Administration has approved its therapy for treating adult patients with a hormone disorder. The company, which has been striving for years to bring this treatment to market, expects the initial supply of the once-daily therapy to be available in the first quarter of 2025. The Danish drugmaker's treatment, Yorvipath, will be the only approved treatment for this condition in the United States once rival Takeda ceases production of its injection, Natpara, at the end of this year. Natpara, initially approved in 2015, has faced unresolved supply issues leading to its discontinuation. The condition, hypoparathyroidism, is a rare endocrine disease caused by low levels of parathyroid hormone that affects multiple organs and is estimated to affect 70,000 to 90,000 people in the United States, according to the company. Low production of parathyroid hormone in hypoparathyroidism results in abnormally low calcium levels in the blood and an increase in phosphorus.